Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide

Table 4

Multivariate Cox regression analysis of PS at the end of first-line treatment, type of relapse, administration of platinum rechallenge, administration of AMR, and number of regimens administered following disease progression after the first-line chemotherapy for postprogression survival.

Factors	Postprogression survival
	Hazard ratio	95% CI	value
PS at the end of first-line treatment	1.39	0.98–1.95	0.06
Type of relapse
Refractory/sensitive	2.24	1.00–5.73	0.04
Administration of platinum rechallenge
Yes/no	0.93	0.33–2.75	0.89
Administration of AMR
Yes/no	1.12	0.41–3.26	0.82
Number of regimens administered following disease progression after the first-line chemotherapy	0.45	0.19–0.91	0.02

95% CI: 95% confidence interval; PS: performance status; AMR: amrubicin.
Bold values are statistically significant ().